| Nov 15 |
Eli Lilly follows JNJ in suing govt. over 340B drug-discount program
|
| Nov 15 |
J&J’s nipocalimab shows promise in Phase II Sjögren’s disease trial
|
| Nov 14 |
Vaccine makers close lower amid reports RFK Jr may head HHS (update)
|
| Nov 14 |
Renaissance Tech adds Micron, exits Broadcom, among Q3 trades
|
| Nov 14 |
Why Is Johnson & Johnson (JNJ) Down 6.7% Since Last Earnings Report?
|
| Nov 14 |
Nipocalimab demonstrates significant clinical improvement in disease activity and IgG reduction in Phase 2 Sjögren's disease study
|
| Nov 13 |
Why Johnson & Johnson, Invitation Homes And Extra Space Storage Are Winners For Passive Income
|
| Nov 13 |
J&J MedTech wins IDE for Ottava to greenlight trials for surgical robot
|
| Nov 13 |
Johnson & Johnson: Tracking Well Above The Industry
|
| Nov 13 |
J&J sues federal government for halting 340B rebate plan
|
